Literature DB >> 26088552

Condurango 30C Induces Epigenetic Modification of Lung Cancer-specific Tumour Suppressor Genes via Demethylation.

Anisur R Khuda-Bukhsh1, Sourav Sikdar.   

Abstract

BACKGROUND: DNA hypermethylation induces cancer progression involving CpG island of DNA and causes inactivation of tumour suppressor genes. In this study, DNA hypermethylation status of lung cancer and ability of ultra-highly diluted Condurango 30C to modulate DNA methylation were ascertained by analysis of lung cancer-specific tumour suppressor genes in respect to placebo.
MATERIALS AND METHODS: DNA methylation status, if any, was determined by PCR-SSCP analyses in lung cancer-specific tumour suppressor genes (p15, p16 and p53) using H460-NSCLC cell and BaP-induced lung cancer of rats. The ability of Condurango 30C to modulate DNA methylation, if any, was verified against placebo control in blinded manner.
RESULTS: Condurango 30C-treated DNA showed significant decrease in band intensity of p15 and p53 genes especially in methylated condition in vitro, at IC50 dose (2.43µl/100µl). SSCP analysis of p15 and p53 genes in Condurango 30C-treated DNA also suggests that Condurango 30C can decrease methylation, in vitro. Inhibition of p15 hypermethylation was observed in post-cancer treatment of rats with Condurango 30C. SSCP results gave a better indication of differences in band position of p15 and p53 in Condurango 30C-treated lung samples.
CONCLUSION: Condurango 30C could trigger epigenetic modification in lung cancer via modulation of DNA hypermethylation.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26088552     DOI: 10.1159/000433485

Source DB:  PubMed          Journal:  Forsch Komplementmed        ISSN: 1661-4119


  2 in total

1.  Deep vein thrombosis cured by homeopathy: A case report.

Authors:  S Choudhury; A R Khuda-Bukhsh
Journal:  J Ayurveda Integr Med       Date:  2020-02-10

Review 2.  The Antitumor Activities of Marsdenia tenacissima.

Authors:  Xiang Wang; Yuanliang Yan; Xi Chen; Shuangshuang Zeng; Long Qian; Xinxin Ren; Jie Wei; Xue Yang; Yangying Zhou; Zhicheng Gong; Zhijie Xu
Journal:  Front Oncol       Date:  2018-10-23       Impact factor: 6.244

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.